Partnering Opportunities

Management intends to assemble a portfolio across immunology, inflammation and opportunistic adjacencies, applying the same restructuring discipline it has executed previously. The discipline is consistent: human-validated assets, definable regulatory paths, milestone-weighted consideration. No such transaction is under binding agreement.